cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Ironwood Pharmaceuticals Inc
4 own
11 watching
Current Price
$9.63
$0.08
(0.84%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,802.01M
52-Week High
52-Week High
12.66000
52-Week Low
52-Week Low
8.07000
Average Volume
Average Volume
1.88M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
4.0198
iconMarket Capitalization1,802.01M
icon52-Week High12.66000
icon52-Week Low8.07000
iconAverage Volume1.88M
iconDividend Yield--
iconP/E Ratio4.0198
What does the Ironwood Pharmaceuticals Inc do?
Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Constella name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout under ZURAMPIC and DUZALLO names. It has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in North America, China, Hong Kong, and Macau; and license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, chronic constipation, and other GI conditions in Japan. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Ironwood Pharmaceuticals Inc make?
News & Events about Ironwood Pharmaceuticals Inc.
Business Wire
3 months ago
Ironwood Pharmaceuticals, Inc. (Ironwood) (Nasdaq: IRWD), a GI-focused healthcare company, and VectivBio Holding AG (VectivBio) (Nasdaq: VECT), a global clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastrointestinal conditions, today...
Business Wire
3 months ago
Ironwood Pharmaceuticals, Inc. (Ironwood) (Nasdaq: IRWD), a GI-focused healthcare company, and VectivBio Holding AG (VectivBio) (Nasdaq: VECT), a global clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastrointestinal conditions, today...
Business Wire
7 months ago
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental New Drug Application (sNDA) for LINZESS (linaclotide) for the treatment of children and adolescents ages...
Zolmax
8 months ago
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD Get Rating) CEO Thomas A. Mccourt sold 110,962 shares of the companys stock in a transaction dated Thursday, January 5th. The stock was sold at an average price of $12.07, for a total transaction of $1,339,311.34. Following the completion of the ...
Frequently Asked Questions
Frequently Asked Questions
What is Ironwood Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Ironwood Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Ironwood Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Ironwood Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Ironwood Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Ironwood Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Ironwood Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Ironwood Pharmaceuticals Inc?
plus_minus_icon
What percentage is Ironwood Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Ironwood Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$9.63
$0.08
(0.84%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc.
$24.74
$-0.03 (-0.12 %)
Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc.
$43.56
$-1.79 (-3.95 %)
FibroGen Inc
FibroGen Inc
$0.86
$-0.11 (-11.21 %)
Xencor Inc
Xencor Inc
$20.14
$-0.36 (-1.76 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc.
$24.74
$-0.03 (-0.12 %)
Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc.
$43.56
$-1.79 (-3.95 %)
FibroGen Inc
FibroGen Inc
$0.86
$-0.11 (-11.21 %)
Xencor Inc
Xencor Inc
$20.14
$-0.36 (-1.76 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00